¶ STAREE: Statins in Reducing Events in the Elderly Mind
¶ Overview
The STAREE trial (Statins in Reducing Events in the Elderly Mind), also known as NCT05586750, is a Phase 4 clinical trial investigating whether atorvastatin can prevent dementia and cognitive decline in elderly individuals. Sponsored by Monash University in Australia, this trial represents a significant effort to identify modifiable risk factors for Alzheimer's disease and related dementias[@staree].
This landmark study addresses one of the most pressing questions in Alzheimer's disease prevention: whether statins—widely prescribed for cardiovascular disease—can also protect against cognitive decline and dementia in older adults who have no existing cognitive impairment. The trial's design addresses key limitations of previous studies that have yielded conflicting results about statin benefits for brain health.
¶ Clinical Trial Details
| Attribute | Value |
|---|---|
| Trial ID | NCT05586750 |
| Official Title | Statins in Reducing Events in the Elderly Mind (STAREE) |
| Sponsor | Monash University |
| Collaborators | National Health and Medical Research Council (Australia) |
| Phase | Phase 4 |
| Status | Active, not recruiting |
| Enrollment | 341 participants |
| Actual Enrollment | 341 participants |
| Condition | Dementia, Alzheimer's Disease, Cognitive Decline |
| Intervention | Atorvastatin 40mg daily |
| Control | Placebo |
| Study Start | June 2022 |
| Estimated Completion | June 2027 |
| Primary Completion | June 2026 |
¶ Trial Design
¶ Study Type
- Design: Randomized, double-blind, placebo-controlled trial
- Duration: 3 years follow-up (minimum)
- Arms:
- Treatment arm: Atorvastatin 40mg daily
- Control arm: Matching placebo
¶ Rationale for Atorvastatin 40mg
The choice of atorvastatin 40mg reflects several considerations:
- Proven cardiovascular efficacy: Atorvastatin 40mg is a standard moderate-to-high intensity dose
- Lipophilicity: Atorvastatin is lipophilic, allowing better penetration across the blood-brain barrier
- Safety profile: Established safety in elderly populations
- Dose-response: Higher doses may provide more central nervous system effects
¶ Participant Flow
¶ Inclusion Criteria
Key inclusion criteria for participant selection:
- Age ≥70 years
- No current diagnosis of dementia or significant cognitive impairment
- MMSE score ≥24 (normal cognitive function)
- Ability to undergo cognitive testing
- Capacity to provide informed consent
- No current statin use (statin-naïve - defined as
months statin use in past 5 years) - No contraindication to statin therapy
- Fluent in English
¶ Exclusion Criteria
-
Cardiovascular indications for statins (per Australian guidelines):
- Known coronary heart disease
- Previous myocardial infarction or stroke
- Established cardiovascular disease requiring lipid-lowering
-
Neurological conditions:
- Current diagnosis of MCI or dementia
- History of neurodegenerative disease (Parkinson's, Huntington's, etc.)
- Significant traumatic brain injury
-
Medical contraindications:
- Active liver disease or elevated LFTs
- Severe renal impairment (eGFR <30 mL/min)
- Previous adverse reaction to statins
- Myopathy or rhabdomyolysis history
-
Medication interactions:
- Use of contraindicated medications with atorvastatin
- Current use of strong CYP3A4 inhibitors
-
Other exclusions:
- Terminal illness with life expectancy years
- Unable to undergo MRI
- Participation in other interventional trials
- Terminal illness with life expectancy
¶ Endpoints
¶ Primary Endpoints
-
Cognitive decline: Change in cognitive function as measured by comprehensive neuropsychological battery
- Primary cognitive measure: Change in global cognition
- Assessment: Detailed neuropsychological testing battery
-
Incident dementia: Development of dementia (all causes) during the study period
- Diagnostic criteria: DSM-V or equivalent
- Adjudication: Expert panel review
-
Brain MRI changes: Volumetric changes in hippocampal and total brain volume
- Primary MRI measure: Hippocampal volume change
- Secondary: Whole brain volume, white matter hyperintensities
¶ Secondary Endpoints
| Category | Endpoint | Assessment |
|---|---|---|
| Cardiovascular | Major adverse cardiac events (MACE) | Clinical events |
| Cognitive | Domain-specific cognitive change | Neuropsychological battery |
| Functional | Daily living activities | ADL, IADL scales |
| Behavioral | Neuropsychiatric symptoms | NPI |
| Quality of Life | Health-related QoL | SF-36, EQ-5D |
| Biomarkers | Blood-based neurodegeneration markers | Plasma Aβ, tau, NfL |
| Brain Imaging | White matter hyperintensities, connectivity | Advanced MRI |
¶ Mechanism of Statins in Neuroprotection
Statins (HMG-CoA reductase inhibitors) exert neuroprotective effects through multiple interconnected mechanisms. Understanding these pathways helps explain why statins might prevent cognitive decline and dementia.
¶ Cholesterol-Lowering Effects
-
Amyloid-beta modulation: Statins may reduce Aβ production by decreasing cholesterol availability for amyloid precursor protein (APP) processing[@simons2002]
- Lipid rafts (cholesterol-rich membrane domains) host β- and γ-secretases
- Reducing cholesterol decreases Aβ generation
- May also enhance Aβ clearance
-
Tau phosphorylation: Cholesterol reduction may decrease tau pathology
- Altered neuronal signaling affects kinase/phosphatase balance
- Reduced hyperphosphorylation of tau
-
Vascular health: Improved cerebral blood flow through reduced atherosclerosis
- Lower circulating LDL reduces atheroma formation
- Improved endothelial function in cerebral vessels
- Enhanced cerebral perfusion
¶ Anti-Inflammatory Effects
Statins have well-documented anti-inflammatory properties that may protect against neuroinflammation:
-
Microglial modulation: Reduced neuroinflammation through decreased cytokine production
- Decreased TNF-α, IL-1β, IL-6 release
- Shift from M1 (pro-inflammatory) to M2 (protective) microglial phenotype
-
NF-κB inhibition: Reduced inflammatory signaling in the brain
- Statins block IKK activation
- Downstream reduction in inflammatory gene expression
-
TREM2 regulation: Potential effects on microglia activity
- TREM2 variants increase AD risk
- Statins may modulate microglial TREM2 expression
¶ Vascular Mechanisms
Given the vascular component of Alzheimer's disease (vascular contributions to cognitive impairment and dementia - VCID):
-
Endothelial function: Improved nitric oxide bioavailability
- Enhanced eNOS activity
- Better vasodilatory responses
-
Blood-brain barrier: Enhanced integrity
- Reduced BBB permeability
- Less perivascular inflammation
-
Cerebral perfusion: Reduced small vessel disease burden
- Decreased white matter hyperintensities
- Improved cerebral blood flow autoregulation
¶ Synaptic Protection
-
Presynaptic function: Cholesterol is essential for synaptic vesicle formation
- Synaptic vesicle membranes are cholesterol-rich
- Reduced cholesterol affects neurotransmitter release
-
Postsynaptic receptors: Membrane fluidity affects receptor function
- NMDA and AMPA receptor function depends on membrane environment
- Improved receptor trafficking and function
-
Neurotrophic support: BDNF expression may be enhanced
- Statins may increase BDNF production
- Supports neuronal survival and plasticity
¶ Antioxidant Effects
- Reduced oxidative stress: Decreased ROS production
- Enhanced antioxidant defenses: Increased Nrf2 pathway activity
- Mitochondrial protection: Improved mitochondrial function
¶ Rationale for the Trial
¶ Epidemiological Evidence
Observational studies have suggested a link between statin use and reduced dementia risk:
| Study Type | Key Finding | Reference |
|---|---|---|
| Meta-analysis | ~30% reduced risk of dementia in statin users | Song 2013[@song2013] |
| Cross-sectional | Lower prevalence of AD in statin users | Wolozin 1993[@wolozin1993] |
| Prospective cohort | Reduced cognitive decline with statins | Haag 2009[@haag2009] |
| Longitudinal | Protective effect in midlife | Li 2020[@li2020] |
- Some studies specifically implicate lipophilic statins (like atorvastatin)
- Timing of statin use (midlife vs. late-life) appears critical
- Dose-response relationships have been observed
¶ Gaps in Evidence
Despite promising observational data, randomized controlled trials have yielded mixed results:
| Trial | Statin | Result | Limitation |
|---|---|---|---|
| PROSPER | Pravastatin | No cognitive benefit | Late-life start, low dose |
| HPS | Simvastatin | No cognitive benefit | Mixed population |
| ASCOT-LLA | Atorvastatin | Neutral | Cardiovascular secondary prevention |
Possible explanations for negative trials:
- Underpowered: Sample sizes too small to detect modest effects
- Wrong population: Patients with established cardiovascular disease may differ
- Inadequate dosing: Lower doses may not provide CNS benefits
- Wrong timing: Late-life intervention may be too late
STAREE aims to address:
- Adequately powered for dementia prevention endpoint
- Statin-naïve elderly participants without established CVD
- Moderate-to-high intensity statin dose (atorvastatin 40mg)
- Focus on primary prevention in healthy elderly
¶ Comparison with Other Statin Trials
| Trial | Design | Population | Statin/Dose | Result | Relevance to STAREE |
|---|---|---|---|---|---|
| PROSPER | RCT, 3.5 years | Age 70-82, history of vascular disease | Pravastatin 40mg | No cognitive benefit | Similar age, but secondary prevention |
| HPS | RCT, 5 years | Age 40-80, with cardiovascular disease | Simvastatin 40mg | No cognitive benefit | Secondary prevention |
| STAREE | RCT, 3 years | Age ≥70, no dementia, statin-naïve | Atorvastatin 40mg | Ongoing | Primary prevention |
| JUPITER | RCT | Older adults with elevated CRP | Rosuvastatin 20mg | Reduced cognitive decline | Hypothesis-generating |
STAREE addresses key limitations of previous trials by:
- Recruiting primary prevention population
- Using adequate dosing
- Focusing on statin-naïve participants
¶ Statistical Considerations
¶ Power Analysis
- Sample size (n=341) calculated to detect 30% relative risk reduction in dementia incidence
- 80% power at α=0.05 (two-sided)
- Accounting for expected dropout (~15%)
- Assumes baseline dementia incidence of ~2% per year in this age group
¶ Analysis Plan
- Primary analysis: Intention-to-treat
- Sensitivity analyses:
- Per-protocol analysis (adherent participants)
- As-treated analysis
- Subgroup analyses:
- Age (70-79 vs. ≥80)
- APOE4 carrier status
- Baseline cognitive function
- Baseline cardiovascular risk
¶ Interim Analyses
- Safety monitoring at regular intervals
- No planned efficacy interim analyses to preserve statistical integrity
¶ Current Status
As of the latest update, STAREE is:
- Status: Active, not recruiting
- Enrollment: 341 participants (fully enrolled)
- Expected completion: June 2027
- Results expected: 2028-2029
¶ Safety Considerations
¶ Expected Adverse Events
| Adverse Event | Frequency | Management |
|---|---|---|
| Myalgia | 5-10% | Dose reduction, discontinuation if severe |
| Headache | 3-5% | Usually transient |
| Nausea | 2-3% | Usually transient |
| Elevated LFTs | 1-2% | Monitor, adjust dose if needed |
¶ Serious Adverse Events (Rare)
- Rhabdomyolysis: Very rare (<0.1%), risk higher with drug interactions
- Liver injury: Rare, monitoring LFTs
- Hemorrhagic stroke: Theoretically possible, but evidence suggests no increased risk
¶ Drug Interactions
Participants are counseled to avoid:
- Strong CYP3A4 inhibitors (clarithromycin, itraconazole, etc.)
- Grapefruit juice
- Certain immunosuppressants
¶ Implications
¶ If Positive
A positive result would:
- Establish statins as a dementia prevention strategy for elderly
- Support early intervention in at-risk populations
- Lead to guideline recommendations for statin use in cognitive health
- Provide cost-effective public health intervention
- Validate HMG-CoA reductase as a therapeutic target
¶ If Negative
A negative result would:
- Argue against routine statin use for dementia prevention in this population
- Emphasize need for other prevention strategies
- Highlight importance of timing (midlife vs. late-life intervention)
- Suggest that cardiovascular benefits do not translate to cognitive benefits
- Focus research on alternative approaches
¶ Considerations for Interpretation
- Type of cognitive outcome matters: Effects on dementia incidence vs. cognitive decline may differ
- Subgroup effects: Some groups may benefit more (e.g., APOE4 carriers)
- Duration of follow-up: 3 years may be insufficient to detect effects
- Competing risks: Cardiovascular death may compete with dementia
¶ Related Pages
- Clinical Trials in Alzheimer's Disease
- Dementia Prevention Strategies
- Lipid Metabolism in Alzheimer's Disease
- Cholesterol and Neurodegeneration
- Cardiovascular Risk Factors for AD
- Statins: Mechanism of Action
- Atorvastatin
- Vascular Contributions to Cognitive Impairment
¶ External Links
- ClinicalTrials.gov - STAREE (NCT05586750)
- Monash University - STAREE
- Australian New Zealand Clinical Trials Registry
- PubMed - Statins and Dementia
¶ References
- Simons M et al., Cholesterol and amyloid-beta pathology. Trends Cell Biol. 2002
- Song Y et al., Statins and cognitive function. JAMA. 2013
- STAREE Trial Information. ClinicalTrials.gov NCT05586750
- Jorm AF et al., Risk factors for dementia. Med J Aust. 2001
- Wolozin B et al., Decreased prevalence of Alzheimer disease with statin use. Arch Neurol. 1993
- Haag MD et al., Statins and risk of dementia. J Neurol Neurosurg Psychiatry. 2009
- Li G et al., Statins and cognitive decline. Ann Neurol. 2020
- Shepardson NE et al., Cholesterol level and statin use in Alzheimer disease. Arch Neurol. 2011